share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

SEC ·  Mar 28 06:10
Summary by Futu AI
Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.